Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2024-04-02 00:00:00 ET · period of report 2024-03-31 · accession 0000905148-24-001057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-02 | 2024-03-31 | ATRA | Gallagher Carol Giltner | Dir | A - Grant | $0.00 | +150.0K | 629.6K | +31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-31 | A | A | 150,000 | $0.00 | 629,608 | D | — | — | (F1) These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service. (F2) This amount includes an additional 20,190 shares that were previously inadvertently omitted from the Reporting Person's aggregate beneficial ownership. |